LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of October 23, 2026, LXRX stock price declined to $1.42 with 2,607,029 million shares trading.

LXRX has a beta of 0.53, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.01 to the broad based SPY ETF.

LXRX has a market cap of $631.84 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $692,000 in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.

LXRX has underperformed the market in the last year with a price return of +1.4% while the SPY ETF gained +14.3%. LXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.3% and -15.5%, respectively, while the SPY returned +3.2% and -2.4%, respectively.

LXRX support price is $1.43 and resistance is $1.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.